Press release
Advanced Renal Cell Carcinoma Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera
DelveInsight's "Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal Cell Carcinoma Market Forecast [https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Advanced Renal Cell Carcinoma Market Report:
*
The Advanced Renal Cell Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In February 2025, Updated results from a phase 1 study (NCT05122546) presented at the 2025 Genitourinary Cancers Symposium revealed that the combination of CBM588 with cabozantinib (Cabometyx) and nivolumab (Opdivo) enhanced progression-free survival (PFS) and objective response rate (ORR) in patients with metastatic renal cell carcinoma (mRCC), though it did not result in a significant rise in Bifidobacterium spp. levels.
*
In December 2024, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotech company focused on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, has announced that the first patient has been dosed in its Phase 1 clinical trial investigating ADI-270 in individuals with metastatic or advanced clear cell renal cell carcinoma (ccRCC)
*
In October 2024, Arcus Biosciences revealed a clinical trial collaboration with AstraZeneca to evaluate the combined use of casdatifan (AB521) and volrustomig in treating patients with clear cell renal cell carcinoma (ccRCC). Casdatifan is Arcus' experimental HIF-2 inhibitor, while volrustomig is AstraZeneca's investigational bispecific antibody targeting PD-1 and CTLA-4. Under the terms of the agreement, AstraZeneca will be responsible for sponsoring and conducting the trial.
*
The Canadian Medical Association Journal (CMAJ) of 2024 states that the occurrence of RCC rises as individuals get older, typically diagnosed around the age of 75 globally. Additionally, males are twice as likely as females to develop this condition.
*
As per the Canadian Medical Association Journal (CMAJ) in 2024, the general survival expectancy for metastatic RCC is roughly 4 years. Nevertheless, this duration may fluctuate based on variables like the patient's age, performance level, and any accompanying health conditions.
*
Key Advanced Renal Cell Carcinoma Companies: Dana-Farber Cancer Institute, Huabo Biopharm Co., Ltd., Beijing Scitech-Mq Pharmaceuticals, Oxford BioMedica, Hutchison Medipharma Limited, Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Pfizer, Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, SCRI Development Innovations, LLC, Astellas Pharma Inc, and others
*
Key Advanced Renal Cell Carcinoma Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others
*
The Advanced Renal Cell Carcinoma epidemiology based on gender analyzed that Males are slightly more affected in the case of Advanced Renal Cell Carcinoma
*
The Advanced Renal Cell Carcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Advanced Renal Cell Carcinoma pipeline products will significantly revolutionize the Advanced Renal Cell Carcinoma market dynamics.
Advanced Renal Cell Carcinoma Overview
Advanced Renal Cell Carcinoma (RCC), also known as advanced kidney cancer, refers to cancer that has spread beyond the kidney and nearby lymph nodes to other parts of the body. Renal cell carcinoma originates in the cells of the kidney's tubules, which are tiny tubes that filter blood and remove waste products to form urine.
Get a Free sample for the Advanced Renal Cell Carcinoma Market Report:
https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market [https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Advanced Renal Cell Carcinoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Advanced Renal Cell Carcinoma Epidemiology Segmentation:
The Advanced Renal Cell Carcinoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Advanced Renal Cell Carcinoma
*
Prevalent Cases of Advanced Renal Cell Carcinoma by severity
*
Gender-specific Prevalence of Advanced Renal Cell Carcinoma
*
Diagnosed Cases of Episodic and Chronic Advanced Renal Cell Carcinoma
Download the report to understand which factors are driving Advanced Renal Cell Carcinoma epidemiology trends @ Advanced Renal Cell Carcinoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Advanced Renal Cell Carcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Advanced Renal Cell Carcinoma market or expected to get launched during the study period. The analysis covers Advanced Renal Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Advanced Renal Cell Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Advanced Renal Cell Carcinoma Therapies and Key Companies
*
Bevacizumab: Dana-Farber Cancer Institute
*
HB0025: Huabo Biopharm Co., Ltd.
*
ST-1898 tablets: Beijing Scitech-Mq Pharmaceuticals
*
Trovax: Oxford BioMedica
*
fruquintinib+sintilimab: Hutchison Medipharma Limited
*
Cabozantinib: Takeda
*
AMG 102: Amgen
*
Pazopanib: Novartis
*
tivozanib (AV-951): AVEO Pharmaceuticals, Inc.
*
Belzutifan: Merck Sharp & Dohme LLC
*
Temsirolimus (CCI-779): Pfizer
*
CB-839: Calithera Biosciences, Inc
*
ABT-869: AbbVie
*
Nivolumab: Bristol-Myers Squibb
*
ABT-510/Thrombospondin-1 mimetic: Abbott
*
bevacizumab: SCRI Development Innovations, LLC
*
CP-461: Astellas Pharma Inc
Discover more about therapies set to grab major Advanced Renal Cell Carcinoma market share @ Advanced Renal Cell Carcinoma Treatment Landscape [https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Advanced Renal Cell Carcinoma Market Strengths
*
The incidence of RCC has increased in recent years leading to more focus by pharmaceutical firms.
*
Antiangiogenics in association with targeted immunotherapy is overcoming resistance emphasizing the role of the tumor microenvironment (TME) and this strategy is currently an option in first line treatment.
Advanced Renal Cell Carcinoma Market Opportunities
*
There are ongoing trials addressing unanswered questions, such as (CAR) T-cell therapy.
Scope of the Advanced Renal Cell Carcinoma Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Advanced Renal Cell Carcinoma Companies: Dana-Farber Cancer Institute, Huabo Biopharm Co., Ltd., Beijing Scitech-Mq Pharmaceuticals, Oxford BioMedica, Hutchison Medipharma Limited, Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Pfizer, Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, SCRI Development Innovations, LLC, Astellas Pharma Inc, and others
*
Key Advanced Renal Cell Carcinoma Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others
*
Advanced Renal Cell Carcinoma Therapeutic Assessment: Advanced Renal Cell Carcinoma current marketed and Advanced Renal Cell Carcinoma emerging therapies
*
Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market drivers and Advanced Renal Cell Carcinoma market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Table of Contents
1. Advanced Renal Cell Carcinoma Market Report Introduction
2. Executive Summary for Advanced Renal Cell Carcinoma
3. SWOT analysis of Advanced Renal Cell Carcinoma
4. Advanced Renal Cell Carcinoma Patient Share (%) Overview at a Glance
5. Advanced Renal Cell Carcinoma Market Overview at a Glance
6. Advanced Renal Cell Carcinoma Disease Background and Overview
7. Advanced Renal Cell Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Advanced Renal Cell Carcinoma
9. Advanced Renal Cell Carcinoma Current Treatment and Medical Practices
10. Advanced Renal Cell Carcinoma Unmet Needs
11. Advanced Renal Cell Carcinoma Emerging Therapies
12. Advanced Renal Cell Carcinoma Market Outlook
13. Country-Wise Advanced Renal Cell Carcinoma Market Analysis (2020-2034)
14. Advanced Renal Cell Carcinoma Market Access and Reimbursement of Therapies
15. Advanced Renal Cell Carcinoma Market Drivers
16. Advanced Renal Cell Carcinoma Market Barriers
17. Advanced Renal Cell Carcinoma Appendix
18. Advanced Renal Cell Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-renal-cell-carcinoma-market-predicted-to-see-upsurge-through-2034-highlights-delveinsight-pfizer-abbvie-bristolmyers-squibb-abbott-takeda-amgen-novartis-aveo-pharma-calithera]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Renal Cell Carcinoma Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera here
News-ID: 4004157 • Views: …
More Releases from ABNewswire
BIS People | Mary - The Magician Of Chinese Education
At BIS, we take immense pride in our team of passionate and dedicated Chinese ducators, and Mary is the coordinate. As the Chinese teacher at BIS, she is not only an exceptional educator but also used to be a highly respected People's Teacher. With over two decades of experience in the field of education, she is now willing to share her educational journey with us.
Image: https://www.bisguangzhou.com/uploads/cambridge-chinese-class-300x200.jpg
Embracing Chinese Culture [https://www.bisguangzhou.com/courses/chinese-studies/] in…
Why Is Regular Maintenance Crucial for LED Screens? Benefits of Routine Maintena …
Proper maintenance of the LED screens must be carried out so that they do not become a waste but function at their full capacity. Screen check-ups performed regularly keep any potential issue, such as dead pixels, unevenness in color or bending of images, from turning into complicated and costly matters. Screens are required for visual inspection and removal of dust or debris in ensuring the images are of the right…
Polycythemia Vera Market to Show Remarkable Growth Trends from 2024 to 2034, Del …
The Key Polycythemia Vera Companies in the market include - Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others.
DelveInsight's "Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Polycythemia Vera, historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU4 (Germany, Spain,…
Presbyopia Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis w …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Presbyopia pipeline constitutes 12+ key companies continuously working towards developing 12+ Presbyopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Presbyopia Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Presbyopia Market.
The Presbyopia Pipeline report embraces in-depth commercial and clinical…
More Releases for Renal
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
Acute Renal Failure Epidemiology Insights to 2025
Publisher " Acute Renal Failure ARF Acute Kidney Injury - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Acute Renal Failure ARF Acute Kidney Injury in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Acute Renal Failure ARF Acute Kidney Injury prevalent or incident cases segmented by age, sex and subpopulations. The Report…
Renal Insufficiency Market Vendor Growth Landscape 2025
Global Renal Insufficiency Market: Snapshot
The demand for renal disease treatment products and therapies has been incrementing steadily in the past few years, owing to the prevalence of poor kidney functions among a vast population base across the world, especially in the Asia Pacific region, and increased government support. However, the participants of the global renal insufficiency market must take a note of weak competition among the marketed products for the…
Acute Renal Failure - Pipeline Review, H1 2018
"The Report Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Acute Renal Failure Market
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)…
Acute Renal Failure Epidemiology Insights to 2025
Publisher " Acute Renal Failure ARF Acute Kidney Injury - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Acute Renal Failure ARF Acute Kidney Injury in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Acute Renal Failure ARF Acute Kidney Injury prevalent or incident cases segmented by age, sex and subpopulations. The Report…
Renal Cluster Drug Development Pipeline Review, 2017
ReportsWorldwide has announced the addition of a new report title
Renal Cluster Drug Development Pipeline Review, 2017 to its growing collection of premium market research reports.
This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and…
